Topica Pharma grabs $27M B round for topical antifungal drug

Aiming to improve the treatment of nail fungus, Topica Pharmaceuticals has rallied venture investors for a $27 million Series B round of financing. The firm plans to use the capital for a 300-patient Phase IIb/III trial of luliconazole, testing to see whether the topical antifungal agent can cure toenail fungus at 52 weeks of treatment. The Palo Alto, CA-based company says its agent is able to penetrate nails and settle into the nail bed, with limited side effects due to low systemic absorption. Article

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.